LG Innovation Ventures

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

Based in the UK, Lab Genius uses a combination of AI, robotic automation, and synthetic biology to develop protein therapeutics. The company’s smart robotic platform, EVA, is capable of designing, conducting, and learning from its own experiments to discover and characterize new molecules with a particular focus on antibody discovery for cancer and inflammatory diseases. This platform technology intelligently navigates the design space using an iterative process called “active learning,” significantly increasing the likelihood of identifying high-performing antibodies more quickly than conventional methods.Key customers and partnershipsLabGenius has entered notable partnerships to enhance its research capabilities and leverage its ML-driven platform. In July 2021, the company announced a multi-year research collaboration with <a href="https://labgeni.us/news-1/pressrelease-sanofi-atzg7">Ablynx </a>, a Sanofi company, to optimize drug candidates focused on inflammation. The company also partnered with <a href="https://www.tillotts.com/news-events/pressrelease/tillotts-pharma-ag-and-labgenius-enter-development-agreement-in-inflammatory-bowel-diseases/">Tillots Pharma AG </a>in March 2019 to discover and develop durg candidates to treat inflammatory bowel diseases (IBD).

AI-based solutions for evolving digital threats

Next-gen Cybersecurity

<div>
 
 Deep Instinct uses artificial intelligence and machine learning to provide threat detection and automated remediation for enterprise endpoints. The company&rsquo;s Deep Neural Network (D-brain) technology detects known and unknown malware, ransomware, and other forms of threats.
 
 
 In March 2021, Deep Instinct started including a performance guarantee to ensure an extremely low false-positive rate and a ransomware warranty of up to USD 3 million per company for a single breach.
 
 
 Key customers and partnerships
 
 
 As of February 2020, the company served customers in the Fortune 500 operating across financial services, healthcare, aviation, insurance, and technology. Deep Instinct partnered with Cloud Distribution in July 2021 to launch its prevention platform through UK channel partners. The company also partnered with Tanium, a cyber asset and inventory management provider in November 2021 to deliver an integrated threat response solution for endpoint security.
 
 
 Funding and financials
 
 
 In September 2022, the company 
 <a href="https://sp-edge.com/updates/13159">
 raised USD 62 million
 </a>
 from BlackRock and Jupiter Fund Management, bringing the total funding raised to USD 322 million. Deep Instinct had plans to further extend this round with additional USD 18 million. Reportedly, this is also the company&rsquo;s last funding round before it looks at going public over 2023, depending on public market conditions.&nbsp;
 
 
 Additionally, the company also made a decision to 
 <a href="https://sp-edge.com/updates/20432">
 lay off 46 employees
 </a>
 , or 16% of its total workforce across Israel, the US and Europe in July 2023 following a management restructuring, and reportedly planned to stop making new hires in Israel.
 
 
 In March 2023, Deep Instinct 
 <a href="https://sp-edge.com/updates/16956">
 received an undisclosed investment from PayPal Ventures
 </a>
 , with the funding expected to be used to accelerate the growth of the company and its threat prevention technology.
 
 
 In 2022, Deep Instinct grew its customer base by three fold, which includes numerous Global 2000 companies spanning across the US, Europe, and Asia-Pacific.
 
</div>

Targeting complex diseases with complex molecules

Large-molecule Therapeutics

LabGenius is a biotechnology company pioneering the use of machine learning for the discovery of novel therapeutic antibodies. The company's proprietary platform, EVA, combines robotic automation, synthetic biology, and artificial intelligence to enable the rapid identification and optimization of high-performing antibodies with non-intuitive designs.
LabGenius addresses a significant challenge in antibody therapeutics – on-target, off-tumor toxicity. While antibodies target diseased cells by binding to surface markers overexpressed on these cells, subpopulations of healthy cells often express the same markers. This can lead to undesirable killing of healthy cells by the therapeutic antibody. The company's platform employs an active learning method called Multi-Objective Bayesian Optimization (MOBO) to co-optimize antibodies across multiple properties, including potency, efficacy, tumor cell selectivity, and developability.
To date, LabGenius has successfully co-optimized mono- and multi-specific single-domain antibodies, demonstrating impressive selectivity and potency improvements over clinical benchmarks. In May 2024, the company announced the delivery of novel highly selective, high-performing VHH-based HER2xCD3 T-cell engagers with over 10,000-fold killing selectivity, representing a more than 400-fold improvement over a relevant clinical benchmark.
LabGenius operates a hybrid business model, collaborating with pharmaceutical partners while advancing its internal pipeline of wholly-owned multispecific antibody assets toward the clinic. The company secured GBP 35 million (USD 40.9 million) in Series B funding in May 2024, led by M Ventures, the strategic venture capital arm of Merck. The funding will enable LabGenius to expand its platform capabilities and facilitate broader strategic partnerships across multiple therapeutic modalities.

LabGenius is a biopharmaceutical company developing protein therapeutics using a machine learning-driven evolution engine. Its protein engineering platform integrates several bleeding-edge technologies from the fields of machine learning, synthetic biology, and robotics.

Deep Instinct applies artificial intelligence’s deep learning to cybersecurity. Leveraging deep learning’s predictive capabilities, Deep Instinct’s on-device solution protects against zero-day threats and APT attacks with unmatched accuracy. Deep Instinct safeguards the enterprise’s endpoints and/or any mobile devices against any threat, on any infrastructure, whether or not connected to the network or to the Internet. By applying deep learning technology to cybersecurity, enterprises can now gain unmatched protection against unknown and evasive cyber-attacks from any source. Deep Instinct brings a completely new approach to cybersecurity enabling cyber-attacks to be identified and blocked in real-time before any harm can occur. Deep Instinct USA is headquartered in San Francisco, California and Deep Instinct Israel is headquartered in Tel Aviv, Israel.

Joyent, a wholly-owned subsidiary of Samsung, helps its customers build and operate modern cloud native applications across multiple clouds. With Joyent, users can experience a new level of operational dexterity and control by leveraging a single infrastructure for managed private cloud, on-premise cloud,  or managed hardware cloud, or a combination. It is the cloud infrastructure that delivers bare-metal performance from a virtual machine, enabling applications to run faster and more reliably than on traditional public or private cloud infrastructure.   In addition, as the corporate steward of Node.js, Joyent offers exclusive debugging and performance tools for Node.js applications. These capabilities, combined with its expertise and global support, transform companies’ ability to manage and scale cloud applications.  Joyent was founded in 2004 by Dean Allen, Jason Hoffman, & David Young. It is headquartered in San Francisco, C.A.

LG Innovation Ventures is a company that specializes in electronic gadgets.

LG Innovation Ventures

Portfolio

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless